BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)
Close on Nov 17, 2026Market cap $2.25MP/E –Yield –
BioNexus Gene Lab r&d expenses
Research and development expenses are spending on new products and technology.
BioNexus Gene Lab's R&D Expenses for the twelve months ending Jun 30, 2026 was $54.13K, up 3.0% year over year. For fiscal 2025 it was $50.67K, up 6.6% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.67K | +6.6% |
| FY2024 | Dec 31, 2024 | $47.51K | -13.6% |
| FY2023 | Dec 31, 2023 | $54.98K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $13.67K | +8.9% |
| Q1 FY2026 | Mar 31, 2026 | $14.49K | +19.3% |
| Q4 FY2025 | Dec 31, 2025 | $11.10K | -36.2% |
| Q3 FY2025 | Sep 30, 2025 | $14.88K | +42.5% |
| Q2 FY2025 | Jun 30, 2025 | $12.56K | +53.2% |
| Q1 FY2025 | Mar 31, 2025 | $12.14K | +5.8% |
| Q4 FY2024 | Dec 31, 2024 | $17.40K | – |
| Q3 FY2024 | Sep 30, 2024 | $10.44K | – |
| Q2 FY2024 | Jun 30, 2024 | $8.20K | – |
| Q1 FY2024 | Mar 31, 2024 | $11.48K | – |
See a number that looks wrong?